NEPHROFLOW
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEPHROFLOW is an injectable diagnostic or therapeutic agent developed by GE HealthCare, approved in 1984 for renal applications. The specific mechanism of action and indications are not publicly detailed in available data, but the injectable route suggests diagnostic imaging or direct renal intervention. Limited clinical activity data indicates this is a mature, legacy product.
LOE Approaching
Product approaching loss of exclusivity with minimal commercial investment signals team downsizing or consolidation within GE HealthCare's portfolio.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEPHROFLOW has zero actively advertised job openings, making it an unattractive career destination for professionals seeking growth or advancement. Assignment to this product suggests a consolidation, wind-down, or niche maintenance role with limited upside.
Company
Worked on NEPHROFLOW at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.